QSI — Quantum-Si incorporated

QSI (Quantum-Si Incorporated) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $258,000, primarily from Platinum instruments and consumable kits.
• Gross Profit: $74,000, resulting in a gross margin of 29%, driven by a higher proportion of consumables.
• Operating Expenses: GAAP total operating expenses were $24.1 million, down from $25.6 million in Q1 2025. Adjusted operating expenses were $21.4 million, compared to $22.9 million in the prior year.
• Cash Position: As of March 31, 2026, cash, cash equivalents, and marketable securities totaled $190.4 million, expected to support operations into 2028.
• Outlook for 2026: Anticipated total revenue of approximately $1 million and adjusted operating expenses of $98 million or less.

2. Strategic Updates and Business Highlights

• Proteus Development: Significant progress made, including successful sequencing on fully integrated Proteus instruments. The platform is expected to outperform the existing Platinum technology in terms of throughput and amino acid detection.
• Market Preparation: Initiatives include a roadshow series to educate potential customers about Proteus, with early events showing strong attendance and interest.
• Customer Engagement: Positive feedback from early access customers on the Proteus prototype, highlighting improvements in amino acid detection and read length compared to Platinum.

3. Forward Guidance and Outlook

• 2026 Focus: Transition year with a focus on consumable utilization, modest new capital sales, and preparing for the Proteus launch.
• Future Expectations: Management expects Proteus to drive long-term revenue growth and profitability. They anticipate a ramp-up in customer volume post-launch, although specific volume predictions remain uncertain.

4. Bad News, Challenges, or Points of Concern

• Revenue Generation: Current revenue is modest, reflecting a strategic decision to prioritize long-term adoption of Proteus over immediate revenue maximization.
• Operating Expense Management: While expenses have decreased, the company is operating at a loss and must manage cash usage carefully as they approach the Proteus launch.
• Market Timing: Customers are timing purchases closer to the availability of Proteus, which could delay revenue recognition.

5. Notable Q&A Insights

• Customer Experience with Proteus: Enhanced capabilities in amino acid detection and read lengths are expected to improve customer applications, particularly in identifying proteins and detecting post-translational modifications.
• Volume Expectations: While Proteus is expected to increase usage among existing Platinum customers, exact volume increases are difficult to predict until the product is in the field.
• Early Access Program: The selection process for early access sites will prioritize diverse market segments, including academic and commercial environments, with a handful of sites expected by summer.
• Roadshow Feedback: Strong interest in Proteus, particularly for applications involving post-translational modifications, with no significant pushback on pricing noted so far.

Overall, QSI is in a transitional phase, focusing on the development and market preparation for its new Proteus platform, while managing financial discipline amid modest current revenues.